Total Payments
$89,976
2024 Payments
$762.22
Companies
35
Transactions
337
Medicare Patients
1,915
Medicare Billing
$209,894
Payment Breakdown by Category
Other$64,575 (71.8%)
Travel$8,359 (9.3%)
Consulting$7,231 (8.0%)
Food & Beverage$6,655 (7.4%)
Research$3,074 (3.4%)
Education$80.86 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $64,575 | 37 | 71.8% |
| Travel and Lodging | $8,359 | 37 | 9.3% |
| Consulting Fee | $7,231 | 4 | 8.0% |
| Food and Beverage | $6,655 | 250 | 7.4% |
| Unspecified | $3,074 | 3 | 3.4% |
| Education | $80.86 | 6 | 0.1% |
Payments by Type
General
$86,901
334 transactions
Research
$3,074
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $22,961 | 39 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $22,512 | 33 | $0 (2019) |
| Lilly USA, LLC | $20,219 | 63 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $12,707 | 32 | $0 (2024) |
| Novo Nordisk AS | $5,273 | 12 | $0 (2019) |
| Eli Lilly and Company | $3,055 | 2 | $0 (2018) |
| Tandem Diabetes Care, Inc. | $682.43 | 8 | $0 (2024) |
| Novo Nordisk Inc | $461.11 | 47 | $0 (2024) |
| Amgen Inc. | $442.89 | 18 | $0 (2024) |
| Medtronic, Inc. | $286.74 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $762.22 | 38 | Amgen Inc. ($122.90) |
| 2023 | $910.20 | 32 | Medtronic, Inc. ($207.31) |
| 2022 | $1,138 | 27 | Lilly USA, LLC ($734.50) |
| 2021 | $34.66 | 2 | Vifor Pharma, Inc. ($22.16) |
| 2019 | $1,976 | 8 | Novo Nordisk AS ($1,492) |
| 2018 | $3,256 | 4 | Eli Lilly and Company ($2,975) |
| 2017 | $81,899 | 226 | AstraZeneca Pharmaceuticals LP ($22,871) |
All Payment Transactions
337 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/31/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.95 | General |
| Category: DIABETES | ||||||
| 10/30/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $15.79 | General |
| Category: Diabetes | ||||||
| 10/28/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: Cardio-renal | ||||||
| 10/23/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $20.93 | General |
| Category: DIABETES MEDICINE | ||||||
| 10/22/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $18.93 | General |
| Category: Diabetes | ||||||
| 09/29/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $23.74 | General |
| Category: DIABETES MEDICINE | ||||||
| 09/18/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $22.12 | General |
| Category: Nephrology | ||||||
| 09/10/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: Diabetes | ||||||
| 09/09/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $21.43 | General |
| Category: Inflammation/Rare Disease | ||||||
| 08/15/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $28.15 | General |
| Category: Endocrinology | ||||||
| 08/13/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.09 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.51 | General |
| Category: Cardio-renal | ||||||
| 08/11/2024 | Tandem Diabetes Care, Inc. | t:slim X2 Insulin Pump with Control-IQ (Device) | Food and Beverage | In-kind items and services | $38.49 | General |
| Category: Endocrinology | ||||||
| 08/01/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $18.91 | General |
| Category: Inflammation | ||||||
| 07/30/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $17.32 | General |
| Category: Bone Health | ||||||
| 07/02/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $13.16 | General |
| Category: Cardio-renal | ||||||
| 06/27/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $25.68 | General |
| Category: DIABETES MEDICINE | ||||||
| 06/26/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $22.89 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 06/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.71 | General |
| Category: DIABETES | ||||||
| 06/05/2024 | Chiesi USA, Inc. | MYCAPSSA (Drug) | Food and Beverage | Cash or cash equivalent | $13.23 | General |
| Category: ACROMEGALY | ||||||
| 05/28/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $21.76 | General |
| Category: Inflammation/Rare Disease | ||||||
| 05/28/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $13.44 | General |
| Category: Diabetes | ||||||
| 05/22/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $20.63 | General |
| 05/08/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $15.75 | General |
| Category: Obesity | ||||||
| 05/07/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $15.92 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $2,975 | 1 |
| SAFETY AND EFFICACY OF HUMAN REGULAR U-500 INSULIN ADMINISTERED BY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION VERSUS MULTIPLE DAILY INJECTIONS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS - A RANDOMIZED, OPEN-LABEL, PARALLEL CLINICAL TRIAL | Eli Lilly and Company | $79.20 | 1 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi | SANOFI US SERVICES INC. | $19.85 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 614 | 837 | $262,981 | $59,824 |
| 2022 | 6 | 538 | 707 | $215,602 | $54,208 |
| 2021 | 5 | 393 | 1,898 | $187,821 | $62,926 |
| 2020 | 3 | 370 | 461 | $98,069 | $32,937 |
Total Patients
1,915
Total Services
3,903
Medicare Billing
$209,894
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 385 | 546 | $200,928 | $44,810 | 22.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 35 | 35 | $22,120 | $5,468 | 24.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 38 | 40 | $14,640 | $3,699 | 25.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 31 | 33 | $16,995 | $3,485 | 20.5% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 86 | 144 | $4,320 | $1,328 | 30.7% |
| 99451 | Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | Office | 2023 | 39 | 39 | $3,978 | $1,035 | 26.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 360 | 478 | $165,398 | $39,841 | 24.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 36 | 36 | $21,240 | $5,758 | 27.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 34 | 40 | $19,240 | $5,508 | 28.6% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 18 | 18 | $4,878 | $1,637 | 33.6% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 78 | 123 | $3,694 | $1,158 | 31.3% |
| 99451 | Telephone or internet assessment with written report by consulting physician, 5 minutes or more | Office | 2022 | 12 | 12 | $1,152 | $306.52 | 26.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 303 | 419 | $141,203 | $35,793 | 25.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 13 | 1,380 | $37,067 | $21,751 | 58.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 40 | 50 | $7,650 | $4,894 | 64.0% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 14 | 24 | $1,176 | $263.58 | 22.4% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 23 | 25 | $725.00 | $223.33 | 30.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 187 | 242 | $77,198 | $17,803 | 23.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 171 | 207 | $20,079 | $14,546 | 72.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 12 | 12 | $792.00 | $588.20 | 74.3% |
About Dr. Harold Cathcart, DO
Dr. Harold Cathcart, DO is a Endocrinology, Diabetes & Metabolism healthcare provider based in Spokane, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1104815935.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Harold Cathcart, DO has received a total of $89,976 in payments from pharmaceutical and medical device companies, with $762.22 received in 2024. These payments were reported across 337 transactions from 35 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($64,575).
As a Medicare-enrolled provider, Cathcart has provided services to 1,915 Medicare beneficiaries, totaling 3,903 services with total Medicare billing of $209,894. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Spokane, WA
- Active Since 10/14/2005
- Last Updated 03/24/2022
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1104815935
Products in Payments
- INVOKANA (Drug) $22,507
- FARXIGA (Drug) $16,773
- HUMULIN (Drug) $16,434
- JARDIANCE (Drug) $16,041
- BYDUREON (Drug) $6,135
- Tresiba (Drug) $3,269
- TRULICITY (Drug) $2,996
- FIASP (Drug) $2,028
- t-slim insulin pump (Device) $576.61
- Korlym (Drug) $163.80
- EVENITY (Biological) $162.68
- Kerendia (Drug) $142.98
- Victoza (Drug) $137.73
- MINIMED 780G (Device) $137.33
- TOUJEO (Drug) $118.54
- FREESTYLE LIBRE 3 (Device) $109.07
- PRADAXA (Drug) $106.70
- INPEN SMART INSULIN DELIVERY SYSTEM (Device) $106.11
- t:slim X2 Insulin Pump with Control-IQ (Device) $105.82
- MOUNJARO (Drug) $104.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Spokane
Carol Wysham, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $962,727
Endocrinology, Diabetes & Metabolism $962,727
Lynn Kohlmeier, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $493,965
Endocrinology, Diabetes & Metabolism $493,965
Mihaela Cosma, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $4,918
Endocrinology, Diabetes & Metabolism $4,918
Dr. Jeffrey Hartman, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $3,830
Endocrinology, Diabetes & Metabolism $3,830
Lisanne Laurier, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $591.64
Endocrinology, Diabetes & Metabolism $591.64
Maria Janout, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $175.57
Endocrinology, Diabetes & Metabolism $175.57